Physician profile
Ryan Daniel Wolfley
NPI 1659035301
$6,531.88
in general payments reported to CMS, 2019-2025
24 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $120 · 2022: $1,532 · 2023: $2,637 · 2024: $2,044 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,823 · Education: $56.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,822.61 |
| Education | $56.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,412.90 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,117.47 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $722.02 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $510.44 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $498.76 | 2022-2025 | Austedo Xr, Uzedy, Austedo |
| Alkermes, INC. | $429.89 | 2022-2024 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $339.88 | 2022-2024 | Invega Sustenna, Invega Trinza |
| Axsome Therapeutics, INC. | $259.54 | 2022-2024 | Auvelity |
| Ironshore Pharmaceuticals INC. | $255.04 | 2022-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $250.42 | 2022-2024 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $151.10 | 2021-2023 | Trintellix |
| Corium, LLC | $101.59 | 2023-2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $87.15 | 2023-2024 | Fanapt, Hetlioz |
| Lundbeck LLC | $73.72 | 2022-2025 | Rexulti |
| Eisai INC. | $69.03 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $58.36 | 2022-2024 | Perseris |
| Biohaven Pharmaceutical Holding Company Ltd. | $54.15 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $43.85 | 2024 | Cobenfy |
| Allergan, INC. | $20.43 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.77 | 2024 | |
| Braeburn INC. | $17.63 | 2024 | Brixadi |
| Sunovion Pharmaceuticals INC. | $15.65 | 2022 | |
| Tris Pharma INC | $12.92 | 2023 | Dyanavel Xr |
| Almatica Pharma LLC | $12.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Wolfley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.